النقرس مع حساسية الألوبيورينول أو عدم تحمله: عندما يفشل العلاج المركب في الوصول إلى هدف حمض البول

References

DOI: 10.1136/annrheumdis-2016-209707

• Febuxostat or a uricosuric are also indicated if allopurinol cannot be tolerated.
• If the SUA target cannot be reached by an appropriate dose of allopurinol, allopurinol should be switched to febuxostat or a uricosuric, or combined with a uricosuric.
• In patients with crystal-proven, severe debilitating chronic tophaceous gout and poor quality of life, in whom the SUA target cannot be reached with any other available drug at the maximal dosage (including combinations), pegloticase is indicated.
• In this study, the percentage of responders (SUA level <6 mg/dL) was 42%, on average, in patients who received pegloticase, 8 mg, every 2 weeks and 0% in the placebo group.
• Effective ULT reduces the size and number of tophi and facilitates their disappearance, thereby improving the quality of life of patients with gout.